These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 15356414)
1. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. Newcomer JW; Nasrallah HA; Loebel AD J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S1-6. PubMed ID: 15356414 [TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Nasrallah HA; Newcomer JW J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S7-14. PubMed ID: 15356415 [TBL] [Abstract][Full Text] [Related]
3. Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia. Sugawara N; Yasui-Furukori N; Yamazaki M; Shimoda K; Mori T; Sugai T; Suzuki Y; Someya T PLoS One; 2014; 9(1):e86826. PubMed ID: 24466260 [TBL] [Abstract][Full Text] [Related]
4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
5. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Citrome L; Kalsekar I; Baker RA; Hebden T Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104 [TBL] [Abstract][Full Text] [Related]
6. [Antipsychotic prescription assessment in general practice: metabolic effects]. Gignoux-Froment F; de Montleau F; Saravane D; Verret C Encephale; 2012 Dec; 38(6):453-9. PubMed ID: 23200610 [TBL] [Abstract][Full Text] [Related]
7. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Patel MX; Nikolaou V; David AS Psychol Med; 2003 Jan; 33(1):83-9. PubMed ID: 12537039 [TBL] [Abstract][Full Text] [Related]
8. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Bou Khalil R Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510 [TBL] [Abstract][Full Text] [Related]
11. [Schizophrenia, diabetes mellitus and antipsychotics]. Gury C Encephale; 2004; 30(4):382-91. PubMed ID: 15538314 [TBL] [Abstract][Full Text] [Related]
12. Factors in antipsychotic drug selection: tolerability considerations. Nasrallah HA CNS Spectr; 2003 Nov; 8(11 Suppl 2):23-5. PubMed ID: 14978455 [TBL] [Abstract][Full Text] [Related]
13. Effects of atypical antipsychotics on weight and serum lipid levels. Meyer JM J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486 [TBL] [Abstract][Full Text] [Related]
14. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V; Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268 [TBL] [Abstract][Full Text] [Related]
15. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. Llorca PM; Lançon C; Hartry A; Brown TM; DiBenedetti DB; Kamat SA; François C BMC Psychiatry; 2017 Feb; 17(1):67. PubMed ID: 28193195 [TBL] [Abstract][Full Text] [Related]